ArticleCancer gene therapy2004
Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells.
Article in Cancer gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 62 citations in OpenAlex.
- Bone sialoprotein: a multifunctional regulator of bone remodelling and tumour progression.Bone research · 2026Review
- Analysis of genetic information from the antlers of Rangifer tarandus (reindeer) at the rapid growth stage.PloS one · 2020Article
- Bone Sialoprotein Shows Enhanced Expression in Early, High-Proliferation Stages of Three-Dimensional Spheroid Cell Cultures of Breast Cancer Cell Line MDA-MB-231.Frontiers in oncology · 2019Article
- IDK1 is a rat monoclonal antibody against hypoglycosylated bone sialoprotein with application as biomarker and therapeutic agent in breast cancer skeletal metastasis.The journal of pathology. Clinical research · 2018Article
- Article
- Mesenchymal stem cells: key players in cancer progression.Molecular cancer · 2017Review
- SIBLINGs and SPARC families: their emerging roles in pancreatic cancer.World journal of gastroenterology · 2014Review
- Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis.Oncotarget · 2014Article
- Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers.Critical reviews in oncology/hematology · 2014Review
- Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.Inflammopharmacology · 2013Review
- Proteins involved in regulating bone invasion in skull base meningiomas.Acta neurochirurgica · 2013Article
- BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells.PloS one · 2013Article
- Silencing of skeletal metastasis-associated genes impairs migration of breast cancer cells and reduces osteolytic bone lesions.Clinical & experimental metastasis · 2012Article
- Sequential biphasic changes in claudin1 and claudin4 expression are correlated to colorectal cancer progression and liver metastasis.Journal of cellular and molecular medicine · 2012Article
- Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma.British journal of cancer · 2011Article
- Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappaB dependent AP-1-mediated ICAM-1 expression in breast cancer cells.Molecular cancer · 2010Article
- Down-regulation of osteopontin attenuates breast tumour progression in vivo.Journal of cellular and molecular medicine · 2008Article
- Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer.Nature reviews. Cancer · 2008Review
- Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.Breast cancer research : BCR · 2008Article
- Bone metastasis: pathogenesis and therapeutic implications.Clinical & experimental metastasis · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteopontin (OPN), bone sialoprotein (BSPII), and osteonectin (ON) belong to a family of glycoproteins, which have been linked to cancer metastasis and progression. Here, we report on the selection of antisense oligonucleotides (ASOs), which are effective in reducing their protein levels. In human MDA-MB-231 breast cancer cells, the maximum inhibition of protein expression ranged from 84% (OPN) to 75% (BSPII) and 70% (ON). Erucylphospho-NNN-trimethylpropanolamine (ErPC3) was used as positive control and combination partner. Exposure to ErPC3 inhibited colony formation of MDA-MB-231 cells by 11% (10 microM), 45% (14 microM) and 78% (20 microM). The clonogenicity of breast cancer cells was reduced by 15%, 11%, 8% (5 microM), 39%, 19%, 14% (10 microM) and 46%, 39%, 21% (20 microM) in response to ASO-OPN-04, ASO-BSPII-06 and ASO-ON-03, respectively. Combination of ErPC3 with the ASOs caused additive combination effects. Pre-exposure to the ASOs, but not to the NSO, inhibited formation of osteolytic metastasis in three of four (ASO-OPN-04, P<0.03) and two of four (ASO-BSPII-06) nude rats, and reduced metastasis lesions significantly (T/C%=4.3 and 9.1, P=0.05, respectively). We conclude that downregulation of OPN and BSPII reduces colony formation of MDA-MB-231 cells and formation of osteolytic metastasis in nude rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.